Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459550 | 1.00 | P2RX7 (0.46) | P2RX7KDM1ATGM2TACR1ITGA4 | |
| SCHEMBL17532278 | 0.89 | P2RX7 (0.52) | P2RX7TGM2ITGA4ITGB7CTSK | |
| SCHEMBL17968782 | 0.84 | ITGB3 (0.49) | P2RX7CTSKITGB3ITGA2B | |
| SCHEMBL17825315 | 0.84 | ITGB3 (0.49) | P2RX7CTSKITGB3ITGA2B | |
| SCHEMBL16294752 | 0.84 | ITGB3 (0.56) | TACR1ITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL17968987 | 0.84 | ITGB3 (0.56) | TACR1ITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL16294750 | 0.84 | ITGB3 (0.56) | TACR1ITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL16343092 | 0.83 | ITGB3 (0.50) | P2RX7CTSKITGB3ITGA2B | |
| SCHEMBL16295738 | 0.83 | ITGB3 (0.50) | P2RX7CTSKITGB3ITGA2B | |
| SCHEMBL22167246 | 0.82 | ALDH1A1 (0.54) | TACR1ITGA4ITGB7CTSKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074820-B | GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112457301-A | Novel GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| EP-3230276-A1 | GLP-1 RECEPTOR MODULATORS | Celgene International II Sarl (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | P2RX7 187/4885KDM1A 2700/4885TGM2 1807/4885 |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | P2RX7 195/4885KDM1A 3106/4885TGM2 1575/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | P2RX7 187/4885KDM1A 2700/4885TGM2 1807/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | P2RX7 183/4885KDM1A 2245/4885TGM2 1648/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | P2RX7 195/4885KDM1A 3106/4885TGM2 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.